Dr. Harvey Pass is a leader in the development of novel treatments for mesothelioma who holds numerous positions with New York University (NYU), including Chief of Thoracic Oncology at the NYU Cancer Center, Chief of the Division of Thoracic Surgery at NYU Langone Medical Center, and Professor of Cardiothoracic Surgery. His laboratory at Bellevue Hospital is the home of the Early Detection Research Network’s Biomarker Discovery Laboratory for Mesothelioma as well as the Clinical CORE for the Mesothelioma Pathogenesis Program Project, both funded by the National Cancer Institute (NCI).
Prior to joining NYU in 2005, Dr. Pass completed a 3-year senior fellowship in the Thoracic Oncology Branch of NCI. Upon completion of his fellowship in 1986, Dr. Pass was appointed Head of Thoracic Oncology for NCI. During his tenure there, he explored the use of intraoperative photodynamic therapy (PDT) for the treatment of pleural mesothelioma as well as the post-surgical use of adjuvant immunochemotherapy for mesothelioma. At NCI, he began a series of ongoing collaborative studies of the molecular biology of mesothelioma.
Dr. Pass joined Karmanos Cancer Institute of Wayne State University in 1996, where he built the thoracic oncology program. Among his many achievements at Karmanos were founding the Mesothelioma Applied Research Foundation (MARF) in 1998 and conducting novel trials and other research for mesothelioma. His research led to the publication of a seminal paper appearing in the New England Journal of Medicine on osteopontin as a biomarker for mesothelioma.
Dr. Pass received his medical degree from Duke University and additional training at the University of Mississippi and the Medical University of South Carolina. He serves as an Ad Hoc reviewer for New England Journal of Medicine, JAMA, and other publications. He has been named one of America’s Top Doctors by Castle Connolly for 5 years.
Visit Mesothelioma Doctors & Hospitals Near You.